Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
  2. Genentech doses first patient in Perjeta and Herceptin Phase 3 study
  3. Combining antibiotics with immune response to treat antibiotic resistant bacteria
  4. May’s top news stories
  5. Algorithm optimises peptides to target drug-resistant bacteria

Latest Content

June’s top news stories

AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).

Getting Acquainted with the Theory of XRF

This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.

Mitochondrial Testing Services

Mitochondria are present in every cell of the body. They maintain cell homeostasis by controlling energy production, ion fluxes and the rate-limiting step of steroidogenesis.

May’s top news stories

Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.

April’s top news stories

Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.

Eligen® Technology Mechanism of Action

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.

March’s top news stories

Aldeyra Therapeutics reported positive data from the Phase III ALLEVIATE trial that evaluated the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution to treat patients with allergic conjunctivitis.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top